3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neoplasms
3
Breast Neoplasms
2
Urologic Neoplasms
1
Thyroid Neoplasms
1
Soft Tissue Neoplasms
1
Sarcoma
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Rhabdomyosarcoma
1
Recurrence
1
Pharyngeal Neoplasms
1
Neurofibromatosis 2
1
Neoplasms, Mesothelial
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphangioleiomyomatosis
1
Lung Neoplasms
1
Kidney Neoplasms
1
Glioma
1
Glioblastoma
1
Erdheim-Chester Disease
1
Endometrial Adenocarcinoma
1
Endocrine Gland Neoplasms
1
Colonic Neoplasms
1
Castleman Disease
1
Carcinoma, Transitional Cell
1
Interventions
Specimen Handling
3
pembrolizumab
2
Magnetic Resonance Spectroscopy
2
Doxorubicin
2
Biopsy
2
talimogene laherparepvec
1
peposertib
1
liposomal doxorubicin
1
fludarabine
1
aldesleukin
1
X-Rays
1
Radiotherapy
1
Radiation
1
Nivolumab
1
Ipilimumab
1
Histamine H2 Antagonists
1
Famotidine
1
Cyclophosphamide
1
CTLA-4 Antigen
1
Angptl4 protein, mouse
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Histiocytoma, Malignant Fibrous
×
temsirolimus
×
30 days
×
Clear all
No trials found.